Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer

[11] Bristow RE(2007)Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease Gynecol Oncol 105 211-106

[12] Chi DS(2006)Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients BMC Cancer 6 153-223

[13] Kayikçioğlu F(2006)Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery J Obstet Gynaecol Res 32 99-410

[14] Kose MF(2005)Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study Int J Gynecol Cancer 15 217-46

[15] Boran N(2002)Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study Eur J Gynaecol Oncol 23 405-420

[16] Onnis A(2010)Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction Gynecol Oncol 118 43-1540

[17] Marchetti M(1993)Primary cytoreductive surgery for epithelial ovarian cancer Obstet Gynecol 61 413-2334

[18] Padovan P(1993)Surgical staging and cytoreductive surgery of epithelial ovarian cancer Cancer 71 1534-572

[19] Schwartz PE(2001)Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study Cancer 91 2329-11

[20] Rutherford TJ(2012)Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery Int J Gynecol Cancer 22 566-91

[11] Bristow RE(2007)Neoadjuvant chemotherapy lessens surgical morbidity in advanced ovarian cancer and leads to improved survival in stage IV disease Gynecol Oncol 105 211-106

[12] Chi DS(2006)Comparison of adjuvant and neoadjuvant chemotherapy in the management of advanced ovarian cancer: a retrospective study of 574 patients BMC Cancer 6 153-223

[13] Kayikçioğlu F(2006)Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery J Obstet Gynaecol Res 32 99-410

[14] Kose MF(2005)Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study Int J Gynecol Cancer 15 217-46

[15] Boran N(2002)Neoadjuvant chemotherapy for advanced epithelial ovarian carcinoma: a retrospective case-control study Eur J Gynaecol Oncol 23 405-420

[16] Onnis A(2010)Ovarian cancer in the elderly: outcomes with neoadjuvant chemotherapy or primary cytoreduction Gynecol Oncol 118 43-1540

[17] Marchetti M(1993)Primary cytoreductive surgery for epithelial ovarian cancer Obstet Gynecol 61 413-2334

[18] Padovan P(1993)Surgical staging and cytoreductive surgery of epithelial ovarian cancer Cancer 71 1534-572

[19] Schwartz PE(2001)Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study Cancer 91 2329-11

[20] Rutherford TJ(2012)Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery Int J Gynecol Cancer 22 566-91